|
11 Jun 2008 - EPIX Pharmaceuticals Initiates Second Trial in Phase 2b Program for Alzheimer's Disease
Three-Month Monotherapy Trial with PRX-03140 to Evaluate Impact on Cognitive Function
complete article »
|
5 Jun 2008 - EPIX Pharmaceuticals Achieves Milestone For Third Discovery Program in Collaboration with GlaxoSmithKline
Using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates to move forward into lead optimization in its third G-protein coupled receptor (GPCR) discovery program. Under the terms of its collaboration with GSK, EPIX is entitled to receive a milestone payment of $3 million for identifying three candidates in this program and an additional $2.5 million for its overall progress in all three of the discovery programs that are part of its collaboration with GSK.
complete article »
|